This clinical trial is focused on studying cervical cancer at stages I to IIA. The trial is investigating a new method for detecting sentinel lymph nodes, which are the first lymph nodes to which cancer cells are likely to spread from a primary tumor. The study will compare the effectiveness of a fluorescent dye called indocyanine green with the current standard methods, which use a radioactive substance known as 99mTc and a blue dye. The purpose of the study is to evaluate how well these methods can detect sentinel lymph nodes during surgery.

Participants in the study will undergo a procedure where the sentinel lymph nodes are identified using the different dyes and substances. The trial will assess the ability of indocyanine green to detect these nodes compared to the traditional methods. This involves using a special imaging technique called near-infrared fluorescence imaging to see the fluorescent dye during the operation. The study will also look at how quickly the detection can be completed with each method and any side effects that might occur.

The trial aims to provide insights into the overall detection rates and the accuracy of the different methods. It will also consider factors like the cost-effectiveness of the procedures and patient satisfaction with the care received. The study is expected to run until the end of 2025, with recruitment starting in April 2024. The findings could help improve the way sentinel lymph nodes are detected in patients with early-stage cervical cancer, potentially leading to better treatment outcomes.